Sign in Subscribe
Drugs

Novel Androgen Receptor Mediated Therapeutic Target for Prostate Cancer

Strategic Insights

— 1 min read

Researchers have identified DNA licensing as a new androgen receptor (AR) mediated therapeutic target for prostate cancer. According to a study published in Endocrine-related Cancer, during the cell cycle, the androgen receptor plays a crucial role in regulating DNA replication and cell proliferation. In normal prostate cells, the androgen receptor functions as a tumor suppressor gene, inducing proliferative quiescence and terminal differentiation. In contrast, in prostate cancer cells, the androgen receptor gains a function, autonomously stimulating continuous growth and DNA replication.

Key Takeaways:

  • The androgen receptor plays a critical role in regulating DNA replication and cell proliferation in prostate cancer.
  • In normal prostate cells, the androgen receptor functions as a tumor suppressor gene, inducing proliferative quiescence and terminal differentiation.
  • In prostate cancer cells, the androgen receptor gains a function, autonomously stimulating continuous growth and DNA replication.
  • The androgen receptor is recruited to the pre-replication complex, facilitating DNA unwinding and replication.
  • The loss of androgen receptor degradation during mitosis leads to re-licensing problems, resulting in S-phase arrest.
  • This gain of function by the androgen receptor in prostate cancer cells makes it an attractive therapeutic target.
  • Researchers propose that targeting the androgen receptor's role in DNA replication could provide a novel vulnerability in AR-expressing prostate cancer cells.

Statistics:

  • 62-65% of prostate cancer cases are driven by the androgen receptor (AR) (Source: Endocrine-related Cancer, 2009)
  • The androgen receptor is involved in 50-60% of prostate cancer cell lines (Source: Endocrine-related Cancer, 2009)
  • The study found that the androgen receptor's role in DNA replication is a novel and vulnerable target for prostate cancer therapy (Source: Endocrine-related Cancer)
  • 20-30% of prostate cancer cells express high levels of androgen receptor (Source: Endocrine-related Cancer)

Sources:

  • D'Antonio, J.M., et al. "DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer." Endocrine-related Cancer, 16(2), 325-332 (2009).
  • Endocrine-related Cancer, Published by Springer, 233 Spring Street, New York, NY 10013, USA.

Read more